Quantcast
Last updated on April 16, 2014 at 8:06 EDT

Latest Prostate cancer Stories

2014-02-04 16:29:22

MADISON, Wis., Feb. 4, 2014 /PRNewswire-USNewswire/ -- Changing its name - but not its focus - the National Lung Cancer Partnership is now Free to Breathe, a name that conveys the organization's passion, dedication and vision to double lung cancer survival by 2022, empower advocates and help every person affected by the disease. "Free to Breathe resonates deeply with people whose lives have been affected by lung cancer, and it embodies who we are and what we do," said Joan H....

2014-02-04 16:28:32

15% Increase in Full-Year Test Volume; 21% Increase in 4th Quarter Test Volume REDWOOD CITY, Calif., Feb. 4, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Product revenue was $67.1 million in the fourth quarter of 2013, compared with $60.0 million for the fourth quarter of 2012, an increase of 12 percent. Total...

2014-02-04 08:34:07

QUÉBEC CITY, Feb. 4, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company's cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone ("LHRH") receptors. The article,...

2014-02-03 23:20:56

Nomedexamlifeinsurance.com (http://nomedexamlifeinsurance.com) announces a new blog, “No Medical Exam Life Insurance For Prostate Cancer Patients.” (PRWEB) February 03, 2014 Nomedexamlifeinsurance.com has released a blog explaining the importance of having life insurance for prostate cancer patients! Prostate cancer patients will have difficulties finding an affordable life insurance plan. They will need to survey many policies and to compare numerous quotes before they can find...

2014-02-03 08:27:25

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement to provide its Decipher(®) prostate cancer test to FEDMED Payors. FEDMED is a national provider network that covers over 40 million lives. The Decipher( )prostate cancer classifier directly measures a patient's biological risk of developing metastatic prostate cancer. GenomeDx, which discovered and developed the Decipher test, will provide laboratory services...

2014-01-30 23:02:32

Mount Sinai experts share tips for prostate cancer prevention and new advancements in treatment and detection. New York, NY (PRWEB) January 30, 2014 Prostate cancer is the second leading cause of cancer death in American men. One in six men will be diagnosed with prostate cancer and 230,000 new cases are diagnosed annually. Overall, the five-year survival rate is 100 percent for men with the disease confined to the prostate or nearby tissue. Expert Available for Interview: Ash Tewari,...

2014-01-30 12:28:48

International studies demonstrate importance of comprehensive tumor profiling for poor-prognosis cancer patients IRVING, Texas, Jan. 30, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present two tumor profiling studies at the 2014 Genitourinary Cancers Symposium held this week in San Francisco, Calif. Through use of the company's comprehensive tumor profiling service, Caris Molecular Intelligence,...

2014-01-30 08:31:31

Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2014 ASCO Genitourinary Symposium SAN DIEGO, Jan. 30, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced new data demonstrating that its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting the probability of developing metastatic prostate cancer, outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy. In addition,...

2014-01-29 16:28:12

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5s2nhx/drug_delivery_in) has announced the addition a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/5s2nhx/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery remains a challenge in management of cancer. Approximately 12.5...

2014-01-29 08:30:13

Experienced biotech financial manager and former investment banker joins executive team as Metamark prepares for ProMark(TM)commercialization CAMBRIDGE, Mass., Jan. 29, 2014 /PRNewswire/ -- Metamark Genetics, Inc., a leader in the discovery of molecular and prognostic tests for cancer, today announced the appointment of Jonathan Lieber as Senior Vice President and Chief Financial Officer. He will report to Metamark President and Chief Executive Officer Shawn M. Marcell and join the...